The inaugural Macrophage-directed Therapies Summit is the only platform dedicated to helping leaders from pharma, biotech and academic institutes to successfully achieve clinical proof of concept when translating macrophage therapies into the clinic whilst ensuring safety, control and effective combination therapies.

Join your macrophage community and discuss strategies to characterize macrophage biology to understand their role in tumor progression and improve targeting precision to prevent off-tumor toxicities.

Network and learn from the trailblazers of macrophage therapeutic development including Carisma Therapeutics, Merck and ALX Oncology across 3 days packed with dedicated, interactive formats exploring the drug development of CD47 checkpoint blockades, engineered macrophages as well as macrophage repolarization and depletion.